
OptimizeRx Corporation – NASDAQ:OPRX
OptimizeRx stock price today
OptimizeRx stock price monthly change
OptimizeRx stock price quarterly change
OptimizeRx stock price yearly change
OptimizeRx key metrics
Market Cap | 77.64M |
Enterprise value | 239.36M |
P/E | -22.61 |
EV/Sales | 3.83 |
EV/EBITDA | -27.94 |
Price/Sales | 4.12 |
Price/Book | 2.04 |
PEG ratio | N/A |
EPS | -1.02 |
Revenue | 78.20M |
EBITDA | -18.67M |
Income | -18.06M |
Revenue Q/Q | 51.42% |
Revenue Y/Y | 26.71% |
Profit margin | -18.32% |
Oper. margin | -19.68% |
Gross margin | 62.4% |
EBIT margin | -19.68% |
EBITDA margin | -23.87% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOptimizeRx stock price history
OptimizeRx stock forecast
OptimizeRx financial statements
Jun 2023 | 13.81M | -4.16M | -30.12% |
---|---|---|---|
Sep 2023 | 16.33M | -2.86M | -17.54% |
Dec 2023 | 28.36M | -4.14M | -14.6% |
Mar 2024 | 19.69M | -6.89M | -35.04% |
Mar 2024 | 19.69M | -6.89M | -35.04% |
---|---|---|---|
Sep 2025 | 29.34M | 3.48M | 11.89% |
Oct 2025 | 28.71M | 2.56M | 8.92% |
Dec 2025 | 40.28M | 8.12M | 20.17% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 121324874 | 5.50M | 4.54% |
---|---|---|---|
Sep 2023 | 123929152 | 7.82M | 6.31% |
Dec 2023 | 183373898 | 56.82M | 30.99% |
Mar 2024 | 176367000 | 53.82M | 30.52% |
Jun 2023 | -2.36M | 3.22M | -7.49M |
---|---|---|---|
Sep 2023 | 1.47M | -1.00M | -349.42K |
Dec 2023 | -6.25M | -26.00M | 36.18M |
Mar 2024 | 2.11M | -153K | -640K |
OptimizeRx alternative data
Aug 2023 | 109 |
---|---|
Sep 2023 | 109 |
Oct 2023 | 109 |
Nov 2023 | 109 |
Dec 2023 | 109 |
Jan 2024 | 109 |
Feb 2024 | 109 |
Mar 2024 | 109 |
Apr 2024 | 109 |
May 2024 | 135 |
Jun 2024 | 135 |
Jul 2024 | 135 |
OptimizeRx other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 4000 |
Dec 2024 | 20000 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Purchase | FEBBO WILLIAM J director, officer.. | Common Stock | 20,000 | $5.01 | $100,220 | ||
Option | ODENCE-FORD MARION officer: General Counsel and CCO | Common Stock | 1,785 | N/A | N/A | ||
Option | ODENCE-FORD MARION officer: General Counsel and CCO | Restricted Stock Units | 1,785 | N/A | N/A | ||
Option | STELMAKH EDWARD officer: CFO/COO | Common Stock | 8,222 | N/A | N/A | ||
Option | STELMAKH EDWARD officer: CFO/COO | Restricted Stock Units | 8,222 | N/A | N/A | ||
Option | STELMAKH EDWARD officer: CFO/COO | Common Stock | 16,622 | N/A | N/A | ||
Option | STELMAKH EDWARD officer: CFO/COO | Restricted Stock Units | 16,622 | N/A | N/A | ||
Option | ODENCE-FORD MARION officer: General Counsel and CCO | Common Stock | 6,649 | N/A | N/A | ||
Option | ODENCE-FORD MARION officer: General Counsel and CCO | Restricted Stock Units | 6,649 | N/A | N/A | ||
Option | SILVESTRO STEPHEN L officer: Chief Co.. | Common Stock | 6,649 | N/A | N/A |
Quarter | Transcript |
---|---|
Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. William J. Febbo (1969) Chief Executive Officer & Director | $626,590 |
Mr. Stephen L. Silvestro (1978) Chief Commercial Officer | $485,560 |
OptimizeRx Aims For Growth After Swoon
OptimizeRx Has A Good Growth Path Ahead
OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio
OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
OptimizeRx (OPRX) Investor Presentation - Slideshow
Red Hot Inflation: Healthcare Stocks You Can Buy
The Stocks To Focus On Today
The Top Stocks You Can Buy Now
One Last Hurrah? The Stocks To Buy Now
-
What's the price of OptimizeRx stock today?
One share of OptimizeRx stock can currently be purchased for approximately $15.7.
-
When is OptimizeRx's next earnings date?
Unfortunately, OptimizeRx's (OPRX) next earnings date is currently unknown.
-
Does OptimizeRx pay dividends?
No, OptimizeRx does not pay dividends.
-
How much money does OptimizeRx make?
OptimizeRx has a market capitalization of 77.64M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 14.53% to 71.52M US dollars.
-
What is OptimizeRx's stock symbol?
OptimizeRx Corporation is traded on the NASDAQ under the ticker symbol "OPRX".
-
What is OptimizeRx's primary industry?
Company operates in the Healthcare sector and Medical - Healthcare Information Services industry.
-
How do i buy shares of OptimizeRx?
Shares of OptimizeRx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are OptimizeRx's key executives?
OptimizeRx's management team includes the following people:
- Mr. William J. Febbo Chief Executive Officer & Director(age: 56, pay: $626,590)
- Mr. Stephen L. Silvestro Chief Commercial Officer(age: 47, pay: $485,560)
-
How many employees does OptimizeRx have?
As Jul 2024, OptimizeRx employs 135 workers, which is 24% more then previous quarter.
-
When OptimizeRx went public?
OptimizeRx Corporation is publicly traded company for more then 17 years since IPO on 28 Nov 2007.
-
What is OptimizeRx's official website?
The official website for OptimizeRx is optimizerx.com.
-
Where are OptimizeRx's headquarters?
OptimizeRx is headquartered at 400 Water Street, Rochester, MI.
-
How can i contact OptimizeRx?
OptimizeRx's mailing address is 400 Water Street, Rochester, MI and company can be reached via phone at +248 6 516 568.
OptimizeRx company profile:

OptimizeRx Corporation
optimizerx.comNASDAQ
135
Medical - Healthcare Information Services
Healthcare
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
Rochester, MI 48307
CIK: 0001448431
ISIN: US68401U2042
CUSIP: 68401U204